Regional therapies for in-transit disease

Area of Science:

• Oncology
• Dermatology
• Surgical Oncology

Background:

• In-transit melanoma is an uncommon but challenging pattern of cancer recurrence.
• It typically manifests as numerous small subcutaneous or cutaneous nodules.
• Management requires specialized approaches due to its unique presentation.

Purpose of the Study:

• To review the management strategies for in-transit melanoma.
• To highlight the role of regional chemotherapy in current treatment paradigms.
• To explore future therapeutic opportunities, including combination therapies and early-phase clinical trials.

Main Methods:

• Review of clinical presentations and current treatment modalities for in-transit melanoma.
• Discussion of the established role of regional chemotherapy.
• Exploration of emerging therapeutic strategies and research platforms.

Main Results:

• In-transit melanoma presents with 1 to over 100 nodules, varying in size.
• Regional chemotherapy is a primary treatment for patients without systemic spread.
• Regional therapy offers a platform for investigating novel treatments in clinical trials.

Conclusions:

• Regional chemotherapy remains a cornerstone for managing in-transit melanoma without distant metastases.
• Future treatment directions involve combining regional therapies with systemic agents and immunomodulators.
• Regional therapy provides a valuable model for early-phase clinical trials of new melanoma therapeutics.